Analytical Data
-
Gene name
MEIS1
- Application
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00470
-
Expression Region
180-320aa
-
Molecular Weight
17.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MEIS1 (Myeloid Ecotropic Viral Integration Site 1) is a transcription factor belonging to the TALE (Three Amino acid Loop Extension) family, which plays a crucial role in hematopoiesis and embryonic development. Research has indicated that MEIS1 is pivotal in regulating gene expression during the differentiation and proliferation of various blood cell lineages. Its aberrant expression has been associated with several hematological malignancies, particularly acute myeloid leukemia (AML). The study of MEIS1 recombinant proteins is essential for understanding its functional role in these processes and its potential as a therapeutic target. Recombinant MEIS1 proteins enable scientists to investigate the molecular mechanisms underlying its interactions with DNA and other transcription factors, as well as its impact on cellular signaling pathways. Moreover, structural studies on MEIS1 can provide insights into its protein-protein interactions, which are crucial for its regulatory functions in the nucleus. The exploration of MEIS1's role in cancer development not only enhances our understanding of leukemogenesis but also paves the way for novel strategies in targeted therapies. Given its significance, ongoing research into MEIS1 recombinant proteins holds great promise for advancing our knowledge of both normal and pathological hematopoiesis, thereby contributing to the development of innovative treatment options for related diseases.
